[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611512":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":84,"collaborators":25,"id":86,"slug":25,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":25,"eligibilityCriteria":91,"healthyVolunteers":87,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":25,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":25,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Arrowhead Pharmaceuticals","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ARO-RAGE","EXPERIMENTAL","ARO-RAGE inhalation",[13],"Drug: ARO-RAGE",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Normal saline (0.9%)",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Inhalation of nebulized solution",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Calculated volume to match active treatment by inhalation of nebulized solution",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Medical Monitor","CONTACT","626-304-3400","ARORAGE-2001@arrowheadpharma.com",[36,48,57,66,75],{"facility":37,"status":38,"city":39,"state":40,"zip":25,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":25},"Research Site 1","RECRUITING","Vancouver","British Columbia","Canada",{"type":43,"coordinates":44},"Point",[45,46],-123.11934,49.24966,{"lat":46,"lon":45},{"facility":49,"status":38,"city":50,"state":25,"zip":51,"country":41,"cosmosGeoPoint":52,"geoPoint":56,"contacts":25},"Research Site 2","Calgary","T2N 4N1",{"type":43,"coordinates":53},[54,55],-114.08529,51.05011,{"lat":55,"lon":54},{"facility":58,"status":38,"city":59,"state":25,"zip":60,"country":41,"cosmosGeoPoint":61,"geoPoint":65,"contacts":25},"Research Site 3","Edmonton","T6G 2G3",{"type":43,"coordinates":62},[63,64],-113.46871,53.55014,{"lat":64,"lon":63},{"facility":67,"status":38,"city":68,"state":25,"zip":69,"country":41,"cosmosGeoPoint":70,"geoPoint":74,"contacts":25},"Research Site 5","Hamilton","L8N 3Z5",{"type":43,"coordinates":71},[72,73],-79.84963,43.25011,{"lat":73,"lon":72},{"facility":76,"status":38,"city":77,"state":25,"zip":78,"country":41,"cosmosGeoPoint":79,"geoPoint":83,"contacts":25},"Research Site 4","Saskatoon","S7M 2W2",{"type":43,"coordinates":80},[81,82],-106.66892,52.13238,{"lat":82,"lon":81},{"type":85,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100611512",false,"NCT07241546","Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma","A Randomized, Double-blind, Placebo-controlled Phase 2a Study of ARO-RAGE Inhalation Solution to Assess Efficacy on Small Airway Dysfunction in Allergen-induced Mild Asthma","Inclusion Criteria:\n\n* Clinically stable, mild atopic asthma (FEV1 ≥70% predicted)\n* Established allergy confirmed by positive skin prick test at screening\n* Willing and able to perform lung function tests and other study-related procedures\n* Participants of childbearing potential must consent to use a method of highly-effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last investigational product administration, whichever is later\n\nExclusion Criteria:\n\n* Concomitant diagnosis of a clinically important pulmonary disease other than asthma\n* Use of corticosteroids, immunosuppressives, or anti-inflammatory medications that interfere with inhaled challenges or inflammation, or chronic use of any other medication for treatment of allergic asthma\n* History or current medical condition contraindicating methacholine challenge\n\nNote: Additional inclusion\u002Fexclusion criteria may apply per protocol.","ALL","18 Years","65 Years",{"count":96,"type":97},36,"ESTIMATED","INTERVENTIONAL",[100],"PHASE2","The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.",[103],"Asthma","2026-06-22",{"date":106,"type":107},"2026-06-23","ACTUAL",{"date":109,"type":107},"2026-03-30",{"date":111,"type":97},"2028-04",{"name":5,"class":6},5]